HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network (Q72792592)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7955519%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

title

HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7955519%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

3

B S Graham

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7955519%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

7

R B Belshe

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7955519%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

1

G J Gorse

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7955519%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

6

S E Frey

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7955519%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

author name string

D H Schwartz

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7955519%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

T J Matthews

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7955519%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

D M Stablein

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7955519%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

M L Clements

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7955519%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

P F Wright

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7955519%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

M Eibl

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7955519%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

publication date

1 November 1994

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7955519%20AND%20SRC:MED&resulttype=core&format=json

Clinical and Experimental Immunology

29 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7955519%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

volume

98

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7955519%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7955519%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

page(s)

178-184

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7955519%20AND%20SRC:MED&resulttype=core&format=json

Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g

29 October 2019

cites work

1 reference

12 December 2020

STUDIES ON ANTIBODY PRODUCTION. XI. VARIATION IN THE SECONDARY RESPONSE AS A FUNCTION OF THE LENGTH OF THE INTERVAL BETWEEN TWO ANTIGENIC STIMULI

1 reference

12 December 2020

Large-scale production and purification of a vaccinia recombinant-derived HIV-1 gp160 and analysis of its immunogenicity

1 reference

12 December 2020

Vaccination against hepatitis B: comparison of three different vaccination schedules

1 reference

12 December 2020

Effect of dose and immunization schedule on immune response of baboons to recombinant glycoprotein 120 of HIV-1.

1 reference

12 December 2020

Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.

1 reference

12 December 2020

The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network

1 reference

12 December 2020

Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients

1 reference

12 December 2020

Enhanced lymphoproliferation to influenza A virus following vaccination of older, chronically ill adults with live-attenuated viruses

1 reference

12 December 2020

Characteristics of a population volunteering for human immunodeficiency virus immunization. NIAID AIDS Clinical Trials Network

1 reference

12 December 2020

Immunization of chimpanzees with the HIV-1 glycoprotein gp160 induces long-lasting T-cell memory

1 reference

12 December 2020

Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody

1 reference

12 December 2020

Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160. The NIAID AIDS Vaccine Clinical Trials Network

1 reference

12 December 2020

Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells

1 reference

12 December 2020

Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. The AIDS Vaccine Clinical Trials Networ

1 reference

12 December 2020

Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network

1 reference

12 December 2020

Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.

1 reference

12 December 2020

Characterization of a vaccinia-derived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees

1 reference

12 December 2020

Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine

1 reference

12 December 2020

Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network.

1 reference

12 December 2020

Considerations in the preparation and use of poliomyelitis virus vaccine

1 reference

12 December 2020

Antigenic potency of poliomyelitis vaccine; influence on degree and duration of vaccine effect

1 reference

12 December 2020

Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.

1 reference

12 December 2020

10.1111/J.1365-2249.1994.TB06122.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7955519%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

1 reference